Analysis of amplicon status using multiplexed FISH in a cohort of tamoxifen treated ER+/HER2- breast cancers.
- Erhan Bilal (158862)
- Kristen Vassallo (158870)
- Deborah Toppmeyer (158877)
- Nicola Barnard (138387)
- Inga H. Rye (158886)
- Vanessa Almendro (158894)
- Hege Russnes (158902)
- Anne-Lise Børresen-Dale (3413)
- Arnold J. Levine (31209)
- Gyan Bhanot (34639)
- Shridar Ganesan (34638)
Publication date
June 2012
DOIAbstract
<p>ER+/HER2- samples with systemic relapse events were probed for the amplification of 8p11.2, 17q22 and 8q24.3 by multiplexed FISH assay as described in Methods. A) Out of 36 samples, 15 had at least one region amplified. Kaplan-Meier curves for relapse free survival is shown for cancers having at least one amplicon vs cancer having no amplicons (HR = 2.31, 95% CI = 0.66–8.06; P = 0.1041 (Gehan-Willcoxon) or P = 0.1886 (Mantel-Cox)). B) A typical image of multicolor FISH in a breast cancer specimen. This cell has evidence of amplification of both 17q23.1 and 8p11 loci, but normal 8q24 loci.</p
Add to ORKG